Drug Development Pipeline
Back to the Drug Development Pipeline
IONIS-ENaC-2.5
Status
Phase TwoTherapeutic Approach
Mucociliary Clearance
IONIS-ENaC-2.5Rx is a compound designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance.
Status
A phase 1/2a study to test the safety and tolerability of IONIS-ENaC-2.5Rx in healthy volunteers and in adults with CF is underway.
Sponsor
This program is sponsored by Ionis Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More